Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dilution? No surprise about a stock sale. The fact that USRM is growing does not mean that they are profitable or cash-flow positive. They have always been short of cash and will continue to be even if things are going well. A stock sale is both good and necessary, assuming the terms are decent.
You're right RR. I'mlLong for quite awhile and I am pretty patient. My feelings about USRM are that they have good science and product. My feelings about management are that they are either no good or that they have had to make some pretty bad or shady deals to stay afloat. So there are two opposing forces operating on this company. I am still betting that the good science will win out over the iffy management, but it's no sure thing.
Funny how markets go. We wait and wait for the big report, it comes out, then nothing happens. No movement, no volume.
If they did not disclose the SEC investigation they would really be in trouble with the SEC!
Smoke does not always imply fire; but fire always implies smoke.
Sorry Dave, but if E-Trade really says this they are in error. USRM is not profitable. I am not certain but I am pretty sure they have never been profitable.
"in my experience, year end extensions usually turn out to be very positive"
Your experience is very different from mine. Mine suggests that they have a problem with their accounting and/or their auditor. If it is a dispute with the auditor, that would be bad indeed.
We can see everything when the next report comes out, but my guess is almost all this compensation comes from exercising options, not cash payments. USRM doesn't have the funds for that!
Does USRM make consumer products? If so, what are they?
.20 would make me very happy at this point!
Not one trade in the last hour? Is that possible?
"one could appropriately seduce" !!!! LOL
The world of penny stocks is entirely new to me, so maybe someone here can answer a question for me. There is lots of talk here of Market Makers manipulating the stock, i.e. holding the price down. How is it in their interest to do that? What's the payoff?
I don't get it. Why is going from 286 clinics to 287 a big deal?
According to Form 4 filings, Tomas controls 38 million shares, Comella 21, and Murphy 8. Most all of these are in unexercised options. The outstanding shares are around 336 million shares. If these directors exercised all their options, they would have about 70 mil of a total of about 400 mil.
Correct me if I'm wrong, but I believe that CEO and Board of USRM hold only a small % of the shares. So far as we know, there is no offer on the table now, so in that sense this is just theoretical.
This has nothing to do with "sectors." The distinction is between a privately-held company and one with a public market for its shares.
I could be wrong, but I believe that both Nest and Boston Dynamics were privately held. If so, the comparison to USRM is irrelevant.
How often do you hear of a buyout for more than double the current price? In my opinion, a buyout in the near future would be the worst possible outcome.
Volume is practically non-existent recently. I think both bulls and bears are waiting to see what FDA does next regarding their complaints against USRM.
Somebody is actually willing to pay for this?
Did I miss something? What happened today that was great for USRM?
Jeff is completely right. Insiders are not loading at all. I don't know why many of you continue to beat this drum. BTW I am also long USRM.
Right you are . Sale/leaseback is also an effective cash-management tool. Whether you are bullish or bearish on USRM one thing is clear: they have almost always been short of cash, so this transaction makes perfect sense. They can use the cash for operations rather than tied up in equipment.
Sdave, as I said, it was "up to" 5 mil. They came up with 1/20th of that, then terminated the agreement in a month. Their investment was not a loan, standby or otherwise; it was clearly stated that they would be purchasing shares.
Apparently, GACP bailed out after investing only $250K. If so, they are certainly not major shareholders. Incidentally, after making a big announcement about GACP planning to invest "up to $5,000,000," don't you think USRM should have told us a month later when GACP bailed out?
Buys are picking up? Volume is barely above zero and trading almost at a halt.
I am lost on this Fidelity thing. Do they limit a trade to 4999 shares? That's less than $200!
My mistake! I misread the MESO release. They are offering $180 million dollars worth of shares, not 180 million shares. Just the same, I think this is a very favorable development for USRM.
I didn't realize that MESO is an Australian company. That means that the ADRs are going to be sold in the U.S. ADRs are a standard way of offering non-US securities here. This seems to be an offering of over a billion dollars. If MESO can do that, I would say it is very positive for USRM.
It probably means they are going to sell 180 million shares outside the United States.
Let me know when you get through to Him. I've got a couple of questions, too.
Would you folks seriously want to be invested in a company whose CEO is spending time responding to random questions from small-time shareholders?
Knowledge and intellectual property rights are not the same thing. Intellectual property created by an employee is normally owned by the employer. So anything proprietary or patentable created at USRM by Kristin will be the property of USRM.
There are lots of people paying cash for many different kinds of stem cell treatments these days. However, the big payoff will come when the insurance companies agree to pay for the treatments. I think that FDA approval is crucial for that.
At a loss to whom? and compared to what?
Tomas suggests that they will not or cannot invest more money into dealing with the FDA. If that is really true, it implies that GACP has either pulled out of USRM or is now calling the tune financially and wants its money invested in clinics, not myocell development. Either way, I would not be surprised to see a company with deeper pockets try to acquire USRM (or its intellectual property rights) at a low-ball price now.
We finally hit 100,000 shares traded! Amazing how little interest there seems to be, bull or bear.
Also known as $80K
Yes, Mel Gibson just bought the company. Your shares will be redeemed at .0769.